https://doi.org/10.55788/38c23c12
A cross-sectional case-control study assessed white matter of patients with migraine using baseline data from the Registry for Migraine (REFORM) study [1,2]. Participants and controls underwent 1 brain MRI session, including diffusion tensor imaging (DTI). White matter was assessed using the Tract Based Spatial Statistics method, which was used to extract 4 values of DTI corresponding to fractional anisotropy (axonal loss or damage), mean diffusivity (tissue damage including demyelination), axial diffusivity (axonal damage or loss), and radial diffusivity (demyelination).
In total, 293 patients with migraine were included, of which 190 had migraine without aura, 103 had migraine with aura, 112 had episodic migraine, and 181 had chronic migraine. All 4 DTI variables were compared between patients with migraine and healthy controls, among migraine subgroups of patients and controls (with vs without aura; aura vs healthy controls; without aura vs controls, chronic vs episodic migraine, chronic vs healthy controls), as well as among subgroups stratified by types of pain (ictal vs no pain episode; ictal pain vs healthy controls; pain side vs pain-free side). The relation to clinical variables, such as mean migraine days, mean headache days, and pain Numerical Rating Scale, was also assessed.
Overall, patients with migraine did not show significant differences in any DTI parameters among the mentioned comparisons. “This is an encouraging finding, and a positive finding for our patients,” said Dr Cédric Gollion (University Hospital Centre of Toulouse, France), as “we can tell them that there are no microstructural abnormalities of the white matter. The fact that there were no correlations between the DTI measures and clinical measurements further reinforces the finding of intact white matter. We can further say that there is no cumulative damage in the course of migraine,” concluded Dr Gollion.
In summary, cerebral white matter was found to be intact in people with migraine, suggesting that structural alterations in white matter do not play a central role in migraine pathophysiology.
- Gollion C, et al. Intact white matter in adults with migraine: a REFORM MRI study. 18th European Headache Congress, 4–7 December 2024, Rotterdam, the Netherlands.
- Karlsson WK, et al. J Headache Pain. 2023 Jun 12;24(1):70.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« More education on migraine features is needed Next Article
New tool adequately captures multiple pain types in trigeminal neuralgia »
« More education on migraine features is needed Next Article
New tool adequately captures multiple pain types in trigeminal neuralgia »
Table of Contents: EHC 2024
Featured articles
More education on migraine features is needed
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Understanding Migraine Mechanisms
The locus coeruleus is involved in processing pain in migraine
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome
Diagnostic and Predictive Tools
AI can enhance migraine diagnosis using easy-to-measure clinical data
New tool adequately captures multiple pain types in trigeminal neuralgia
MRI analyses suggest that migraine is not associated with altered brain white matter
More education on migraine features is needed
Treatment Innovations
PACAP-targeting therapies: a future option for migraine?
Rapid complete responses with atogepant
Cabergoline is a potential add-on treatment option in patients with migraine
Nitroglycerin-induced migraine targetable by different agents
Rimegepant reduces migraine symptoms through 1 year of treatment
Fremanezumab is a treatment option for paediatric patients with episodic migraine
What brain changes are associated with fremanezumab treatment success?
Preventative Therapies in Real-world Context
Low discontinuation rates with preventative galcanezumab in a real-world setting
Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders
Biofeedback training can reduce affected days in episodic migraine
Virtual reality interventions can reduce pain perception of chronic headache
Risk Factors and Long-term Management
Can predisposing factors be targeted to reduce new migraine incidence?
Active migraine comes at a high cost in Spain
Many patients, including non-responders, prefer triptans over non-headache-specific medication
Systemic Conditions and Migraine
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Related Articles
December 7, 2020
Later school start time linked to fewer migraines in adolescents
September 9, 2020
Unmet needs and pipeline
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
